Interleukin-33 in human gliomas: Expression and prognostic significance

DOROTHEE GRAMATZKI¹, KARL FREI², GIERI CATHOMAS³, HOLGER MOCH⁴, MICHAEL WELLER¹⁵ and KIRSTEN DIANA MERTZ³⁴

¹Laboratory for Molecular Neuro-Oncology, Department of Neurology; ²Department of Neurosurgery, University Hospital Zurich, 8091 Zurich; ³Institute of Pathology Liestal, Cantonal Hospital Baselland, 4410 Liestal; ⁴Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich; ⁵Neuroscience Center Zurich, University of Zurich, 8091 Zurich, Switzerland

Received August 8, 2015; Accepted April 29, 2016

DOI: 10.3892/ol.2016.4626

Abstract. Interleukin-33 (IL-33) is a nuclear and pleiotropic cytokine with regard to its cellular sources and its actions. IL-33 is involved in the pathogenesis of brain diseases. Several factors account for the tumorigenicity of human gliomas, including cytokines and their receptors. The present study assessed the expression and prognostic significance of IL-33 in human astro-glial brain tumors. Protein levels of IL-33 were determined by immunohistochemistry using a tissue microarray containing 95 human gliomas. mRNA expression data of IL-33, as well as of its receptors, IL-1 receptor-like 1 protein and IL-1 receptor accessory protein (IL1RAcP), were obtained from The Cancer Genome Atlas database. IL-33 protein was expressed heterogeneously in tumor tissue, but was, however, not detected in normal brain tissue. There was no differential IL-33 protein expression by tumor grade, while IL-33 protein expression was associated with inferior survival in patients with recurrent glioblastomas. Interrogations of the TCGA database indicated that mRNA expression of IL-33 and the IL-33 receptors was heterogeneous, and that IL-33 and IL1RAcP mRNA levels were correlated with the tumor grade. Elevated IL-33 mRNA levels were associated with the inferior survival of glioblastoma patients. Therefore, IL-33 may play an important role in the pathogenesis and prognosis of human gliomas.

Introduction

Glioblastoma is the most common primary brain tumor, with an annual incidence of 3.9 cases per 100,000 individuals in the Canton of Zurich (1) and the most aggressive among all gliomas. The standard of care includes radiotherapy plus concomitant and maintenance temozolomide chemotherapy (TMZ/RT→TMZ) (2), resulting in a median survival time of 16 months in clinical trial populations (3). Several factors account for the tumorigenicity of gliomas, including mutations in selected genes, the amplification of signaling pathway genes, and the exploitation of surrounding non-transformed brain cells induced to provide molecules essential for glioma growth and invasiveness (4,5). Among these, cytokines and their receptors have received significant attention (6,7). For instance, interleukin (IL)-1β, IL-6 and IL-8 are expressed by glioma cells and regulate glioma cell survival, migration and invasion (8,9). However, the expression and function of other IL-1 family members, such as IL-33, in human glioma cells have not been addressed in detail.

IL-33 is recognized for its pro-inflammatory role in inflammatory diseases of mucosal tissues, including allergic asthma, inflammatory bowel diseases and eosinophilic esophagitis (10-14), but also in rheumatoid arthritis and sarcoidosis (15). IL-33 signals through a heterodimeric receptor consisting of IL-1 receptor-like 1 protein (IL1RL1) and IL-1 receptor accessory protein (IL1RAcP). Binding of IL-33 to the receptor activates nuclear factor-κB and mitogen-activated protein kinases, in a myeloid differentiation primary response gene 88-dependent manner (16-18).

IL-33 is predominantly and constitutively found in the nucleus of endothelial or epithelial cells of barrier tissues (17,19-21). It mediates the recruitment and activation of immune cells such as mast cells, monocyes, eosinophils, neutrophils, dendritic cells and lymphocyte subsets (16,22). IL-33 can also exert multiple effects on non-immune cells (19-21). Beyond the extracellular receptor-mediated function of IL-33, these effects also appear to be receptor-independent. In this case, IL-33 acts as an intracellular repressor of transcription (12,20,21,23,24).

The role of IL-33 in the human brain is not well known. IL-33 levels were found to be overexpressed in the brain of patients with Alzheimer’s disease (25) and multiple sclerosis (26). In the central nervous system (CNS) of mice, IL-33 is constitutively expressed by astrocytes and endothelial cells (17,27), and it can be induced in astrocytes in response...
to inflammatory and necrotic stimuli (28). Since growing evidence indicates that IL-33 plays a role in the maintenance and homeostasis of astrocytes (27–30), it may also contribute to the development and progression of tumors derived from astrocytes. The function of IL-33 in human cancer has remained controversial, but elevated serum levels of IL-33 have been reported in malignancies such as gastric cancer, hepatocellular carcinoma and non-small cell lung cancer (31–33). Recently, it was shown that growth rate and colony formation of tumorigenic C6 rat glioma cells were attenuated by the inhibition of IL-33 gene expression and that IL-33 induced migration in these cells (34). In the present study, the expression and prognostic significance of IL-33 in gliomas was investigated.

**Materials and methods**

**Patients.** In accordance with the Institutional Review Board, and following the retrieval of informed consent, the surgical specimens and clinical records were retrieved from 95 patients who underwent brain tumor resection between January 2000 and December 2009 at the Department of Neurosurgery, University Hospital Zurich (Zurich, Switzerland). In total, 10 astrocytomas of World Health Organization (WHO) grade I (AI), 14 astrocytomas of WHO grade II (AII), 23 anaplastic astrocytomas (astrocytomas of WHO grade III; AAIHII) and 48 glioblastomas were analyzed. The group of glioblastoma patients included 26 newly diagnosed patients and 22 patients with recurrent tumors. In 1 patient, primary and recurrent tumor specimens were obtained. All tumors were classified and graded according to the WHO classification of tumors of the central nervous system (35). Tissues of 4 patients, not diagnosed with brain tumors, were retrieved during autopsy and used as normal brain controls.

**Immunohistochemistry.** Immunohistochemistry was performed on a tissue microarray (TMA) with archival formalin-fixed 4-µm thick sections on SuperFrost slides (Menzel-Glaser, Braunschweig, Germany). Deparaffinized, rehydrated sections were precultivated on the BondMax system (Leica, Mannheim, Germany) in Bond Epitope Retrieval Solution 2 (pH 9.0) for 30 min at 95°C and then stained for IL-33 using goat anti-human IL-33 immunoglobulin (Ig)G (catalog no. AF3625; R&D Systems Inc., Minneapolis, MN, USA) at a dilution of 1:400. The specificity of IL-33 staining was confirmed by negative staining with isotype-matched IgG (catalog no. AB-108-C; R&D Systems Inc.). The immunostaining results were assessed as the percentage of IL-33-positive (IL-33⁺) cells (nuclear staining) (21). Scoring was performed by one scientist in a blinded manner.

**Interrogations of The Cancer Genome Atlas (TCGA) database.** Microarray and outcome data were obtained from the glioblastoma data set of the TCGA database was performed using the Kaplan-Meier analysis module of the R2 microarray analysis and visualization platform (http://r2.amc.nl). The cut-off to segregate glioblastoma patients into two groups with high or low expression of the target gene was defined by the average expression level of the target gene.

**Statistics.** Progression-free survival (PFS), overall survival (OS) and post-recurrence survival (PRS) curves were estimated by the Kaplan-Meier method and compared with the two-sided log-rank test. PFS time was calculated from the date of surgery to the date of recurrence. OS time was measured from the date of first surgery to the date of mortality. PRS time was measured from the date of the surgery in which the tissue was obtained to the date of mortality. Patients without confirmed mortality were censored for OS and PRS at the last follow-up visit. Patients without documented progression were censored at the last follow-up visit for PFS, PRS and OS. The Kruskal-Wallis test (one-way analysis of variance for non-parametric values), in combination with Dunn's multiple comparison test, was used to compare protein or mRNA levels within groups. Survival-associated analyses were calculated with the log-rank test. All statistical analyses were performed using Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). P < 0.05 was considered to indicate a statistically significant difference.

**Results**

**Patient and tumor characteristics.** Tissue sections of 95 patients from a single center with newly diagnosed or recurrent glioma were analyzed, and the patient characteristics are presented in Table I. Glioblastoma patients were older (median age, 56.5 years) than patients diagnosed with WHO grade I (median age, 20 years), WHO grade II (median age, 37.5 years) or WHO grade III (median age, 41 years) tumors. In the group of WHO grade II-IV patients, males were more often affected than females. The median OS time in the group of glioblastoma patients (14 months) was worse than that for patients diagnosed with WHO grade III gliomas (41 months). The median OS time for patients with WHO grade II was 14.3 years, whereas the median survival time for patients diagnosed with WHO grade I was 22 years. The median OS time in the group of newly diagnosed glioblastoma patients was 10 months, while in the group of recurrent glioblastoma patients, the median OS time was 22 months. The PRS time for recurrent glioblastoma patients was 5 months.

**IL-33 is expressed in human gliomas and is associated with inferior survival in patients with recurrent glioblastoma.** Protein levels of IL-33 were assessed by immunohistochemistry using a TMA (Fig. 1A and B). The TMA cores of normal brain tissue showed a number of IL-33-negative (IL-33⁻) neuronal cells and only very few, scattered, normal astrocytes with weak nuclear IL-33 expression. When captured on the TMA, infiltrating immune cells were negative. The IL-33 mean labeling indexes in the tumor cells were 13.3% (range, 0-65%); 95% confidence interval (CI), 2.2-28.7) for A1, 15.4% (range 0-70%; 95% CI, 2.6-28.1) for AII, 19.7% (range, 0-60%; 95% CI, 9.2-30.2) for AAIHII and 21.7% (range, 0-92.5%;
Table I. Patient characteristics.

| Characteristic | I (n=10) | II (n=14) | III (n=23) | IV (n=48) | IV nd (n=26) | IV rec (n=22) |
|----------------|---------|----------|-----------|-----------|-------------|-------------|
| Age at diagnosis, years | | | | | | |
| Median | 20.0 | 37.5 | 41.0 | 56.5 | 58.5 | 53.0 |
| Range | 1-29 | 23-69 | 24-75 | 18-80 | 21-80 | 18-79 |
| Gender, n | | | | | | |
| Male | 5 | 10 | 13 | 16 | 17 | |
| Female | 5 | 4 | 10 | 15 | 10 | 5 |
| Survival, months (events) | | | | | | |
| Median OS | 264 (2) | 172 (3) | 41 (12) | 14 (39) | 10 (21) | 22 (18) |
| (95% CI) | - | - | - | (2.9-7) | (2.9-6) | (3-14.2) |
| Median PRS | n. a. | n. a. | n. a. | n. a. | n. a. | 5 (18) |
| (95% CI) | | | | | (4.0-10.1) | |

WHO grades I-IV correspond with AI, AII, AAIII and glioblastoma tumors, respectively. WHO, World Health Organization; events, number of patients with confirmed death; OS, overall survival; PRS, post-recurrence survival; CI, confidence interval; nd, newly diagnosed; rec, recurrent; n.a., not applicable.

95% CI, 13.1-30.3) for glioblastoma (Fig. 1B). Thus, the highest mean IL-33 labeling indexes were observed in glioblastoma, but these did not differ significantly from gliomas of other grades. When newly diagnosed and recurrent tumor samples for glioblastoma patients were analyzed separately, the mean percentages were 19.4% (range, 0-92.5%; 95% CI, 8.9-29.9) for newly diagnosed tumors and 24.4% (range, 0-90%; 95% CI, 9.4-39.5) for recurrent tumors (Fig. 1C). Based on the percentages of the IL-33 labeling indexes, patients were divided into two groups: Negative (0%) and positive (≥1%) for IL-33. The ratios of IL-33+ to IL-33− patients per WHO grade were as follows: AI, 50/50; AII, 57/43; AAIII, 57/43; and glioblastoma, 48/52. Nuclear IL-33 was also regularly found in endothelial cells of vessels that were randomly captured on TMA cores of tumor and normal brain tissues (data not shown).

To search for an association between IL-33 labeling indexes and survival, patients with glioblastoma were divided into two groups, defined as positive or negative for this cytokine. Patient characteristics of IL-33 negative (0%) and positive (≥1%) for IL-33. The ratios of IL-33+ to IL-33− patients were analyzed. The median mRNA expression levels of IL-33+ patients were 6.6% (95% CI, 5.8-6.7) for normal brain tissues, 6.8% (95% CI, 5.3-6.9) for AI, 7.3 (95% CI, 6.7-7.5) for AII, 6.4 (95% CI, 5.8-6.6) for AAIII and 7.0 (95% CI, 6.7-7.1) for glioblastoma (Fig. 2A). The median IL-33 mRNA expression levels varied significantly (P=0.02), but multiple comparisons between each tumor grade did not demonstrate statistically significant results (Fig. 2A).

Next, the IL-33 receptors, IL1RL1 and IL1RAcP, were analyzed. The median mRNA expression levels of IL1RL1 were 6.2 (95% CI, 5.3-6.9) for normal brain tissues, 6.8 (95% CI, 5.3-6.8) for AI, 7.3 (95% CI, 6.5-7.5) for AII, 6.4 (95% CI, 5.8-6.6) for AAIII and 7.0 (95% CI, 6.7-7.1) for glioblastoma (Fig. 2B). mRNA levels were not increased or decreased in any of the analyzed groups compared with each
other. By contrast, the median IL1RAcP mRNA levels were increased in the glioblastoma patients compared with that of the patients diagnosed with AII (P<0.01) or AAIII (P<0.01). The median mRNA expression levels of IL1RAcP were 5 (95% CI, 4.6-5.3) for normal brain tissues, 8.4 (95% CI, 7.1-8.9) for AI, 5.7 (95% CI, 5.3-6.4) for AII, 6.6 (95% CI, 6.4-7.1) for AAIII and 7.9 (95% CI, 7.6-8) for glioblastoma (Fig. 2C). A correlation in mRNA expression levels was found between IL-33 and IL1RAcP (r=0.14, P=0.02), but not between IL-33 and IL1RL1 (r=0.08, P=0.20). There were no correlations between the IL-33 receptors (r=-0.04, P=0.52) (Fig. 2D).

Finally, microarray and outcome data for glioblastoma were obtained from the TCGA database. Patients were divided into two groups with high or low IL-33 mRNA expression. The cut-off was defined by the average mRNA expression level of the target gene. Patients with higher IL-33 mRNA expression...
| Characteristic                        | Newly diagnosed | Recurrent |
|--------------------------------------|-----------------|-----------|
|                                      | IL-33<sup>-</sup> | IL-33<sup>+</sup> | IL-33<sup>-</sup> | IL-33<sup>+</sup> |
|                                      | (n=12)          | (n=14)    | (n=11)     | (n=11)        |
| Age, years                           |                 |           |            |               |
| Median                               | 63              | 57        | 50         | 59            |
| Range                                | 21-77           | 41-80     | 21-63      | 18-79         |
| Age groups, n (%)                    |                 |           |            |               |
| ≤40 years                            | 1 (8.3)         | 0 (0.0)   | 3 (27.3)   | 3 (27.3)      |
| 41-50 years                          | 2 (16.7)        | 4 (28.6)  | 3 (27.3)   | 0             |
| 51-60 years                          | 3 (25.0)        | 4 (28.6)  | 3 (27.3)   | 4 (36.4)      |
| 61-70 years                          | 1 (8.3)         | 3 (21.4)  | 2 (18.2)   | 3 (27.3)      |
| >70 years                            | 5 (41.7)        | 3 (21.4)  | 0 (0.0)    | 1 (9.1)       |
| Gender, n (%)                        |                 |           |            |               |
| Female                               | 1 (8.3)         | 9 (64.3)  | 1 (9.1)    | 4 (36.4)      |
| Male                                 | 11 (91.7)       | 5 (35.7)  | 10 (90.9)  | 7 (63.6)      |
| KPS (pre-operative), n (%)           |                 |           |            |               |
| 90-100                               | 1 (8.3)         | 1 (7.1)   | 5 (45.5)   | 3 (27.3)      |
| 70-80                                | 8 (66.7)        | 11 (78.6) | 5 (45.5)   | 7 (63.6)      |
| <70                                   | 3 (25.0)        | 2 (14.3)  | 1 (9.1)    | 1 (9.1)       |
| Tumor localization, n (%)            |                 |           |            |               |
| Frontal                              | 2 (16.7)        | 3 (21.4)  | 1 (9.1)    | 4 (36.4)      |
| Parietal                             | 0 (0.0)         | 2 (14.3)  | 3 (27.3)   | 0 (0.0)       |
| Temporal                             | 3 (25.0)        | 7 (50.0)  | 5 (45.5)   | 5 (45.5)      |
| Occipital                            | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Brainstem                            | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Cerebellar                           | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Spinal                               | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Multifocal (>2 regions)              | 5 (41.7)        | 2 (14.3)  | 2 (18.2)   | 2 (18.2)      |
| Surgery, n (%)                       |                 |           |            |               |
| Biopsy                               | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Partial resection                    | 2 (16.7)        | 2 (14.3)  | 1 (9.1)    | 2 (18.2)      |
| Subtotal resection                   | 9 (75.0)        | 2 (14.3)  | 3 (27.3)   | 6 (54.5)      |
| Gross total resection                | 1 (8.3)         | 10 (71.4) | 7 (63.6)   | 2 (18.2)      |
| No data                              | 0 (0.0)         | 0 (0.0)   | 0 (0.0)    | 1 (9.1)       |
| First-line therapy, n (%)            |                 |           |            |               |
| No therapy                           | 2 (16.7)        | 2 (14.3)  | 1 (9.1)    | 2 (18.2)      |
| RT alone                             | 1 (8.3)         | 6 (42.9)  | 2 (18.2)   | 1 (9.1)       |
| RT→TMZ                               | 3 (25.0)        | 1 (7.1)   | 3 (27.3)   | 2 (18.2)      |
| TMZ/RT                               | 0 (0.0)         | 3 (21.4)  | 2 (18.2)   | 0 (0.0)       |
| TMZ/RT→→TMZ                          | 8 (66.7)        | 1 (7.1)   | 3 (27.3)   | 6 (54.5)      |
| TMZ alone                            | 0 (0.0)         | 1 (7.1)   | 0 (0.0)    | 0 (0.0)       |
| No data                              | 1 (8.3)         | 0 (0.0)   | 0 (0.0)    | 0 (0.0)       |
| Post-second or -third surgery treatment<sup>a</sup>, n (%) |                 |           |            |               |
| No therapy                           |                 |           | 2 (18.2)   | 1 (9.1)       |
| TMZ/RT→→TMZ                          |                 |           | 1 (9.1)    | 1 (9.1)       |
| TMZ alone                            |                 |           | 5 (45.5)   | 5 (45.5)      |
| Lomustine alone                      |                 |           | 2 (18.2)   | 0 (0.0)       |
| Gefitinib alone                      |                 |           | 0 (0.0)    | 1 (9.1)       |
| Bevacizumab plus irinotecan          |                 |           | 0 (0.0)    | 2 (18.2)      |
| No data                              | 1 (9.1)         |           | 1 (9.1)    |               |
Table II. Continued.

| Characteristic | Newly diagnosed | Recurrent |
|---------------|----------------|-----------|
|               | IL-33<sup>−</sup> | IL-33<sup>+</sup> | IL-33<sup>−</sup> | IL-33<sup>+</sup> |
|               | (n=12)          | (n=14)    | (n=11)          | (n=11)          |
| Survival      |                |            |                |                |
| Median follow-up, months | 12            | 7.5        | 27             | 14             |
| Median PFS, months (events) (95% CI) | (1.9-8.9)     | (0.9-5)    | (3.27-9)       | (3-12)         |
| Median PRS, months (events) (95% CI) | n.a.          | n.a.       | (3.9-54.9)     | (-)            |
| Median OS, months (events) (95% CI) | (1.9-19.8)    | (3.8-11.9) | (9.9-30.5)     | (-)            |
| Alive at last follow up, n (%) | 1 (8.3)       | 4 (28.6)   | 4 (36.4)       | 0 (0.0)        |

*Data are reported from the date of the surgery in which the tissue was obtained. IL-33, interleukin-33; TMZ, temozolomide; PFS, progression-free survival; PRS, post-recurrence survival; OS, overall survival; events, number of patients with confirmed progression or death; CI, confidence interval; RT, radiotherapy; -, negative; +, positive; n. a., not applicable; KPS, Karnofsky performance score. TMZ/RT→TMZ, radiotherapy plus concomitant and maintenance temozolomide chemotherapy.

Figure 2. IL-33 mRNA expression in human gliomas: An analysis of The Cancer Genome Atlas (TCGA) network. (A) Interleukin-33 (IL-33), (B) IL-1 receptor-like 1 protein (IL1RL1) and (C) IL-1 receptor accessory protein (IL1RAcP) mRNA expression levels of normal brain (NB), World Health Organization grade I (A1), II (AII) and III astrocytomas (AIII), and glioblastomas (grade IV astrocytomas) were obtained from the TCGA database. Box plots are shown (median, range). Values are represented in a logarithmic scale. P-values were assessed using the Kruskal Wallis test. (D) Pairwise correlation was assessed among mRNA data of IL-33, IL1RL1 and IL1RAcP. Two-tailed Spearman test coefficients (r) and significances (p) are indicated. Values are represented in a logarithmic scale. (E) Kaplan-Meier survival curves of overall survival are shown for the group of glioblastoma patients. Patients were divided into two groups with high (blue line) vs. low (red line) IL-33 mRNA expression. The cut-off was defined by the average mRNA expression level of the target for glioblastoma. Target genes were IL-33, IL1RL1 or IL1RAcP (P<0.05 was considered significant). *P<0.05; **P<0.01; ***P<0.001; n.s., not significant.
levels experienced inferior survival (P=0.016). IL1RL1 and IL1RAcP mRNA expression levels were not associated with survival in the group of glioblastoma patients (Fig. 2E).

Discussion

Members of the IL-1 family (e.g., IL-1β, IL-6 and IL-8) are expressed by glioma cells and modulate survival, migration and invasion (8). IL-33, another IL-1 family member, is a pleiotropic cytokine that may be involved in the pathogenesis of brain diseases (38). IL-33 is a pro-inflammatory mediator activating microglia, and inducing inflammatory cytokines and chemokines, and thus may have neuroprotective or neurotoxic effects depending on tissue conditions. In a previous study, the increased expression of IL-33 contributed to enhanced cell growth of rat glioma cells and the invasion of microglia (34). Moreover, exogenously administrated IL-33 enhanced primary tumor growth and inhibited innate antitumor immunity in a metastatic breast cancer model (39).

The purpose of the present study was to assess IL-33 expression in human astroglial brain tumors and to evaluate its prognostic significance. Normal brain sections were found to be negative for IL-33 protein expression. The high level IL-33 detection in certain astrocytomas suggested a pathogenic role for this cytokine (Fig. 1B). On the other hand, similar levels of IL-33 across all WHO grades showed IL-33 production to be independent of the grade of malignancy. Furthermore, protein levels of IL-33 were markedly similar among newly diagnosed and recurrent glioblastomas, indicating that treatment in this patient population does not significantly affect its expression (Fig. 1C). IL-33 protein labeling indexes were not associated with PFS in the glioblastoma patients (Fig. 1D). However, in the subgroup of recurrent glioblastoma patients, IL-33+ tumors demonstrated inferior OS and PRS compared with IL-33- tumors (Fig. 1E and F). This could indicate that IL-33 expression may be an important feature for advanced glioblastoma patients. In line with these indications, IL-33 is known to enhance tumor surveillance and antitumor immunity (40,41). Therefore, IL-33 may contribute to tumor progression and antitumor activity, depending on the levels of IL-33 and the microenvironment. The microenvironment of gliomas in situ comprises not only stromal CNS-intrinsic cell types, such as astrocytes and microglial cells, but also inflammatory cells that have infiltrated into the tumor from the circulation, including lymphocytes, macrophages, neutrophils and eosinophils (42,43). Although these infiltrating immune cells may seek to curb tumor growth initially, evidence points to the tumor subsequently affecting the immune cells to allow its growth. Necrosis or inflammation in the CNS causes the release of IL-33, particularly from astrocytes and glioma cells. However, since there is a population of resident mast cells in the CNS (44,45), it would also lead to the secretion of IL-33 by the mast cells. This could have profound effects in glioma progression since IL-33 may then in turn act not only on astrocytes, but also on tumor cells and possibly other CNS glial cells to induce STAT6-responsive genes to complete an important, neural-immune circuit (46).

TCGA interrogation in the present study indicated that the mRNA levels of IL-33, as well as those of IL1RAcP, are upregulated in human glioblastoma (Fig. 2A and C), and that IL-33 mRNA expression correlates with IL1RAcP mRNA expression (Fig. 2D), suggesting that there may be an IL-33 autocrine loop in CNS tumors derived from glial cells, particularly astrocytes (28). TCGA also made it possible to delineate an association between IL-33 mRNA expression and inferior survival in glioblastoma patients (Fig. 2E), suggesting that the IL-33-expressing phenotype defines a glioma subset with a more aggressive course and a worse prognosis.

Angiogenesis is another hallmark of glioblastoma. Notably, Choi et al demonstrated that IL-33 promotes angiogenesis and vasopermeability in vivo and in vitro (47). Endothelial cells are a source of IL-33 and also express the heterodimeric IL1RL1 (27). In the present study, IL-33 was not expressed in all endothelial cells of normal brain and intra-peritumoral glioma vessels, but this could not be addressed systematically since vessels were not captured on all TMA cores, and the TMA was designed to study tumor tissues. The TMA-based approach allowed for large-scale analysis of multiple human glioma cases. However, the approach is by nature limited to the study of IL-33 expression in the tumor area selected on the TMA. Therefore, a systematic evaluation of different tumor subregions (e.g., necrotic or vascular areas) was not possible.

The present study data suggested that IL-33 may play a role in human glioma development, growth and progression. This could be due to IL-33-mediated communication between glioma cells and components of the tumor microenvironment, such as resident astrocytes, microglia and inflammatory or endothelial cells. Alternatively, IL-33 overexpression in glioma could be a bystander effect reflecting a more general disease-associated phenomenon, as IL-33 is upregulated in other neurological conditions as well (48). The complex interactive network of IL-33 and the extent to which the IL-33/IL1RL1/IL1RAcP axis can be affected by therapeutic intervention will require elucidation in human glioma.

Acknowledgements

The authors thank Melanie Sachs (Institute of Pathology Liestal, Cantonal Hospital Baselland, Liestal, Switzerland) and Martina Storz (Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zürich, Switzerland) for their expert technical assistance. This study was supported by a grant from Oncosuisse (no. KLS 3110-02-2013) and by a Filling-the-Gap personal grant from the University of Zurich.

References

1. Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D, Rohrmann S, et al: Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer: Apr 18, 2016 (Epub ahead of print).
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma multiforme. N Engl J Med 352: 987-996, 2005.
3. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, et al: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15: e395-e403, 2014.
4. Huse JT and Holland EC: Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331, 2010.
5. Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia 59: 1169-1180, 2011.
6. Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang L, Ji G, Song SW, Qin X, et al: A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol 114: 199-208, 2013.
7. Prosniaik M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbauka K, Apanasovitch TV, Heber-Katz E, Curtis MT, Cotzia P and Hooper DC: Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 19: 3776-3786, 2013.
8. Yeung YT, McDonald KL, Grewal T and Munoz L: Interleukins in glioblastoma pathophysiology: Implications for therapy. Br J Pharmacol 168: 591-606, 2012.
9. Zhao F, Arif MG and Li M: Understanding the role of cytokines in glioblastoma multiforme pathogenesis. Cancer Lett 316: 139-150, 2012.
10. Schiering C, Krausgruber T, Chomka A, Adelmann K, Cotzia P and Hooper DC: The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513: 564-568, 2014.
11. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R and Hermoso MA: Characterization of the novel ST2-IL33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097-1107, 2010.
12. Palmer G and Gabay C: Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7: 321-329, 2011.
13. Préfontaine D, Nadigel J, Chourilly F, Aubouin S, Sentilhay A, Chakir J, Martin JC and Hamid Q: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 125: 752-754, 2010.
14. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, Wu K, You Y, Alevy Y, Girard JP, et al: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123: 3967-3982, 2013.
15. Kempf W, Zolinger T, Sachs M, Ullmer E, Cathomas G, Dirnhofer S and Mertz KD: Granulomas are a source of interleukin-33 expression in pulmonary and extrapulmonary sarcoidosis. Hum Pathol 45: 2202-2210, 2014.
16. Moulin D, Donzeé T, Talabot-Ayer D, Mézín F, Palmer G and Gabay C: Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225, 2007.
17. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, Mcclanahan TK, Zarowski G, Mosbrett M, Qin J, Li X, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490, 2005.
18. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pilzsch A and Kastelein RA: IL-1 receptor accessory protein and ST2 comprise the complex. J Exp Med 193: 175-182, 2001.
19. Küchler AM, Pollehnier J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H and Haraldsen G: Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173: 1229-1242, 2008.
20. Moussion C, Ortega N and Girard JP: The IL-1-like cytokine IL33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel ‘alarmin’? PLoS One 3: e3331, 2008.
21. Perrier VE, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G and Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104: 282-287, 2007.
22. Alves-Filho JC, Söное F, Souto FO, Freitas A, Verri WA Jr, de Rooi JJ, de Rooi JM, Morpur MP and Weiner DB: Allergic IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 74: 1789-1800, 2014.
23. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, Shi G, Xia X, Wu L and Zhang L: Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 335: 446-453, 2013.
24. Curran CS and Bertics PF: Eosinophils in glioblastoma biology. J Neuroinflammation 9: 11, 2012.
25. Hussain SF, Yang D, Suki D, Aldape K, Grimm E and Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8: 261-279, 2006.
26. Dong H, Zhang X and Qian Y: Mast cells and neuroinflammation. Med Sci Monit Basic Res 20: 200-206, 2014.
27. Skaper SD, Facchi L and Giusti P: Mast cells, glia and neuroinflammation: Partners in crime? Immunology 141: 314-327, 2014.
28. Merkel BC, Owens JL, Lopes MB, Silva CM and Hussaini IM: STAT3 expression in glioblastoma promotes invasive growth. BMC Cancer 11: 184, 2011.